Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of semaglutide injection for weight management in adults with obesity without diabetes
CTR20244146Phase 3Completed
- Sponsor
- Huisheng Biopharmaceutical
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, sponsored by Huisheng Biopharmaceutical. Started Feb 2025; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20244146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244146.